Talaris Therapeutics, Inc. (CIK: 0001827506) EDGAR, Information, Filings... CompaniesBIO.Com

Talaris Therapeutics, Inc.

Mailing address
93 WORCESTER STREET, WELLESLEY, Delaware, 02481
Phone
502-398-9250
State location
Kentucky
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Filings
N/A

Talaris Therapeutics, Inc. (CIK: 0001827506) is an American company incorporated in the state of Kentucky. Head office is located at 570 PRESTON ST., SUITE 400, LOUISVILLE, Kentucky, 40202. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). Talaris Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Smith Karen L.	0001639637	May-16-2022	director
SCHWARZMAN STEPHEN A	0001070844	May-06-2021	10 percent owner
MCDADE MARK	0001242126	May-06-2021	director
GALAKATOS NICHOLAS	0001252522	May-06-2021	director
ENRIGHT PATRICK G	0001253886	May-06-2021	10 percent owner
Nader Francois	0001365343	May-06-2021	director
Fenton Mary Kay	0001378589	May-06-2021	officer: Chief Financial Officer
Blackstone Group Inc	0001393818	May-06-2021	10 percent owner
Blackstone Group Management L.L.C.	0001404071	May-06-2021	10 percent owner
Tammenoms Bakker Juliet	0001431159	May-06-2021	10 percent owner
Blackstone Holdings I L.P.	0001464694	May-06-2021	10 percent owner
Blackstone Holdings I/II GP L.L.C.	0001464695	May-06-2021	10 percent owner
Blackstone Holdings II L.P.	0001484870	May-06-2021	10 percent owner
Srivastava Sapna	0001569226	May-06-2021	director
Clarus Lifesciences III, L.P.	0001597143	May-06-2021	10 percent owner
Clarus Defined Exit I, L.P.	0001615352	May-06-2021	10 percent owner
Clarus DE II, L.P.	0001619527	May-06-2021	10 percent owner
Clarus Ventures III GP, L.P.	0001620148	May-06-2021	10 percent owner
Requadt Scott	0001664852	May-06-2021	director, officer: See Remarks
Longitude Venture Partners III, L.P.	0001674099	May-06-2021	10 percent owner
Clarus IV-D, L.P.	0001700717	May-06-2021	10 percent owner
Clarus IV-C, L.P.	0001700718	May-06-2021	10 percent owner
Clarus IV-B, L.P.	0001700719	May-06-2021	10 percent owner
Clarus IV-A, L.P.	0001700720	May-06-2021	10 percent owner
Longitude Capital Partners III, LLC	0001713663	May-06-2021	10 percent owner
Shah Gaurav	0001725922	May-06-2021	director
MACKAY GEOFFREY	0001741849	May-06-2021	director
Blackstone Clarus III L.L.C.	0001762202	May-06-2021	10 percent owner
Clarus IV GP L.P.	0001793305	May-06-2021	10 percent owner
Blackstone Clarus GP L.P.	0001793311	May-06-2021	10 percent owner
Blackstone Clarus GP L.L.C.	0001793316	May-06-2021	10 percent owner
Zdanowski Michael	0001845662	May-06-2021	officer: Chief Technology Officer
Krieger Nancy	0001845672	May-06-2021	officer: Chief Medical Officer
Ildstad Suzanne	0001845822	May-06-2021	director, 10 percent owner, officer: Chief Scientific Officer
Agarwala Sandip	0001845965	May-06-2021	director, 10 percent owner
Blackstone Clarus DE L.L.C.	0001857665	May-06-2021	10 percent owner
Clarus Ventures DE GP, L.P.	0001857754	May-06-2021	10 percent owner

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Talaris Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
S-8	Document	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans Acc-no: 0001827506-25-000032 (33 Act) Size: KB	Mar-13-2025	333-285796 25736643
10-K	Document	Annual report pursuant to section 13 and 15(d) Acc-no: 0001827506-25-000027 (34 Act) Size: KB	Mar-13-2025	001-40384 25733925
8-K	Document	Current report filing Acc-no: 0001827506-25-000025 (34 Act) Size: KB	Mar-13-2025	001-40384 25733869
SCHEDULE 13G/A	Document	Acc-no: 0001140361-25-004891 (34 Act) Size: KB	Feb-14-2025	005-92543 25630758
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001827506-25-000014 ( Act) Size: 0 KB	Feb-04-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001827506-25-000012 ( Act) Size: 0 KB	Jan-29-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001827506-25-000011 ( Act) Size: 0 KB	Jan-29-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001827506-25-000010 ( Act) Size: 0 KB	Jan-29-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001827506-25-000009 ( Act) Size: 0 KB	Jan-29-2025
8-K	Document	Current report filing Acc-no: 0001827506-24-000108 (34 Act) Size: KB	Dec-10-2024	001-40384 241538543
8-K	Document	Current report filing Acc-no: 0001827506-24-000105 (34 Act) Size: KB	Dec-10-2024	001-40384 241537229
EFFECT	Document	Acc-no: 9999999995-24-003490 (33 Act) Size: KB	Nov-14-2024	333-283078 241465709
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001104659-24-119304 (34 Act) Size: KB	Nov-14-2024	005-92543 241464727
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001140361-24-046975 (34 Act) Size: KB	Nov-14-2024	005-92543 241464098
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000905148-24-003171 (34 Act) Size: KB	Nov-14-2024	005-92543 241463230
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001172661-24-004774 (34 Act) Size: KB	Nov-14-2024	005-92543 241457902
SC 13G	Document	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000902664-24-006532 (34 Act) Size: KB	Nov-14-2024	005-92543 241457861
CORRESP	Document	A correspondence can be sent as a document with another submission type or can be sent as a separate submission. Acc-no: 0001827506-24-000103 ( Act) Size: KB	Nov-12-2024
UPLOAD	Document	Acc-no: 0000000000-24-012541 ( Act) Size: KB	Nov-12-2024	333-283078
SC 13G	Document	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0002012383-24-003482 (34 Act) Size: KB	Nov-08-2024	005-92543 241439621

Recent 20 filings. View all Talaris Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Talaris Therapeutics, Inc. overview
Talaris Therapeutics, Inc. job
Talaris Therapeutics, Inc. stock
Talaris Therapeutics, Inc. ownership
Talaris Therapeutics, Inc. CEO
Talaris Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.